Boston scientific acquired celonova on (b)(4) 2015.As part of the acquisition, a retrospective review of post-market complaints was completed by bsc on (b)(4) 2016.This specific event was not previously identified by celonova as meeting reporting criteria.When evaluated by bsc, it was assessed as meeting reporting criteria and is being reported within 30 days of the (b)(4) 2016 review.(b)(4).Device evaluated by mfr: it is indicated that the device will not be returned for evaluation.A review of the batch history, historical trending, and similar complaint trending review for the product family will be conducted.If there is any further relevant information from that review, a supplemental medwatch will be filed.(b)(4).
|